PRKCI — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Staurosporine (SCHEMBL8156)	1.00	9/20
Staurosporine (SCHEMBL8157)	1.00	9/20
SCHEMBL100287	0.44	9/20
SCHEMBL117745	0.56	7/20
SCHEMBL115053	0.56	6/20
SCHEMBL65106	0.48	6/20
SCHEMBL100506	0.48	6/20
SCHEMBL101776	0.47	6/20
Fasudil (SCHEMBL4674)	1.00	5/20
SCHEMBL100651	1.00	5/20
SCHEMBL190590	1.00	5/20
SCHEMBL190415	0.63	5/20
SCHEMBL78989	0.62	5/20
Phorbol (SCHEMBL72895)	0.62	5/20
SCHEMBL190414	0.62	5/20
SCHEMBL101224	0.60	5/20
SCHEMBL91443	0.59	5/20
SCHEMBL101085	0.43	5/20
SCHEMBL102204	0.42	5/20
SCHEMBL99690	1.00	4/20

Clinical trials — most relevant to PRKCI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	PHASE4	UNKNOWN
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Dietary Fish Protein in Subjects With Insulin Resistance	PHASE2	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Fat Induced Insulin Resistance and Atherosclerosis	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Influence of Intermittent Hypoxia on Glycemic Control	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKCI binder may also engage these)

Protein	Name	Similarity
Q5R4K9	—	1.000	Q5R4K9 →
Q62074	—	1.000	Q62074 →
F1M7Y5	—	1.000	F1M7Y5 →
O19111	—	1.000	O19111 →
Q90XF2	—	1.000	Q90XF2 →
Q02956	—	1.000	Q02956 →
P09217	—	1.000	P09217 →
PRKCZ	Protein kinase C zeta type	1.000	landscape →
Q19266	—	1.000	Q19266 →
A8WUG4	—	1.000	A8WUG4 →
A1Z9X0	—	1.000	A1Z9X0 →
Q8BRK8	—	0.997	Q8BRK8 →
Q09137	—	0.994	Q09137 →
Q02111	—	0.994	Q02111 →
Q5RD00	—	0.993	Q5RD00 →
P54645	—	0.993	P54645 →
P13678	—	0.993	P13678 →
Q39030	—	0.992	Q39030 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.992	landscape →
Q6PFQ0	—	0.992	Q6PFQ0 →
PRKAA2	5'-AMP-activated protein kinase catalytic subunit alpha-2	0.992	landscape →
Q6TJY3	—	0.992	Q6TJY3 →
Q28948	—	0.992	Q28948 →
O08875	—	0.992	O08875 →
P09215	—	0.992	P09215 →
P07934	—	0.992	P07934 →
Q09639	—	0.992	Q09639 →
Q8BSK8	—	0.992	Q8BSK8 →
Q64682	—	0.992	Q64682 →
Q66I46	—	0.992	Q66I46 →